Navigation Links
CeNeRx BioPharma Completes $15 Million Series B Financing
Date:10/17/2008

- New Funds Will Support Phase II Trial of Novel Antidepressant Tyrima(TM) and Advancement of Cannabinoid Compounds -

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $15 million Series B financing. Existing investors Aisling Capital, L Capital Partners and Pappas Ventures participated in the funding round. CeNeRx plans to use the proceeds to conduct a Phase II clinical trial of its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD), to further characterize its novel preclinical cannabinoid pipeline and potentially to acquire additional development stage compounds targeted at CNS disorders.

"This successful Series B financing is a validation of the excellent progress we are making in advancing Tyrima, which we believe has the potential to be an important new option in the $15 billion antidepressant market," said Mark Baric, President of CeNeRx. "We appreciate the vote of confidence shown by our existing investors who all participated in the financing. These funds provide the resources we need to continue the positive momentum we have been achieving in our clinical and preclinical programs."

Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A). In a separate press release issued today, CeNeRx announced the initiation of a Phase II clinical trial to evaluate the antidepressant efficacy of Tyrima in patients with MDD.

"We welcome this opportunity to invest in CeNeRx's progress as it begins a Phase II trial of Tyrima, which has the potential to be the first triple-action antidepressant with a safety profile appropriate for use by the many patients inadequately served by current treatments," said Steven A. Elms, CeNeRx Board Cha
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lilly Recognized as One of the Worlds Top Biopharmaceutical Employers
2. Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
3. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
4. Helix Biopharma Closes $11.4 Million Private Placement
5. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
6. Helix BioPharma Announces $11.4 Million Private Placement
7. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
8. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
9. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
10. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the addition ... Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET ... (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & ... report to their offering. ...
(Date:6/18/2013)... MA (PRWEB) June 18, 2013 ... an automated system for rapid bacterial strain typing, ... has joined the company as Vice President of ... integration for the company’s RESOLUTION™ Microbial Genotyping ... includes the benchtop instrument, pathogen-specific assay kits, database ...
(Date:6/18/2013)... 2013 NuView Life Sciences (NLS), a ... vitro diagnostic (IVD) biomarkers, today announced the results from ... in development for the early detection of Prostate and ... oral presentation at the 2013 Annual Meeting of the ... Vancouver, Canada on Sunday, June 9th. NLS acquired ...
(Date:6/17/2013)... As a leader in the skincare industry, the team ... for acne, rosacea, and eczema. As part of Acne and ... Rosacea Society) has dedicated a month to creating awareness about ... on treatment options. Probiotic Action follows in the footsteps of ... via social networks and online resources for the acne and ...
Breaking Biology Technology:North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 2PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 3NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2
... Perceptive Informatics , a leading eClinical solutions ... PRXL ), today unveiled the new release ... provides richer functionality to further streamline the clinical trial ... clinical trial sponsors to more efficiently manage the clinical ...
... films ever made on a device the size of an ... could make it possible to build radically smaller storage devices ... devices. There,s just one obstacle on the way. Nano-sized magnets ... hairs above absolute zero. Now a chemistry student at the ...
... March 28, 2011 DRIVE4COPD, the nation,s single largest ... named PRWeek,s Healthcare Campaign of the Year ... the most prestigious honors in the public relations industry, ... and education teams.  Boehringer Ingelheim Pharmaceuticals, Inc. is the ...
Cached Biology Technology:Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 2Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 3Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 4Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 5Heavy metals open path to high temperature nanomagnets 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 3DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 4
(Date:6/17/2013)... -- As mobile devices, smartphones and tablets become ... exponentially, and biometric authentication offers that security, according ... Insider ( www.heavyreading.com/mobile-networks ), a subscription research ... ). Biometrics Offer Promise for More ... on smartphones, analyzing the most lucrative verticals for ...
(Date:6/17/2013)... Entrepreneurship will be the topics under discussion during ... For the third consecutive year, this will be ... of experiences among members of Academy, Business, Educators, ... Confirmed speakers: Elisa Martn Garijo (IBM South Europe), ... and Mary O,Donovan (Hovione), among others. E3 Forum ...
(Date:6/16/2013)... 16, 2013)Male mice who were fed a high-fat diet ... who also had higher levels of body fat, a ... observed primarily in male offspring, despite their consumption of ... meeting of The Endocrine Society in San Francisco, Calif. ... affect metabolism and behavior of offspring dependent on the ...
Breaking Biology News(10 mins):Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 3'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Obese male mice father offspring with higher levels of body fat 2
... trials ever, researchers have found that an experimental vaccine ... of shingles--a painful nerve and skin infection--and dramatically reduced ... the disease. The findings appear in the June 2 ... The Shingles Prevention Study, conducted over 5 ½-years, was ...
... for pandemic influenza, a new study reports for the first ... spread from poultry to humans. The research appears in ... now available online. , Crossing the species barrier is an ... pandemic potential. Previous studies have focused on the ability of ...
... Two peas in a pod may not be so friendly when ... plant, once separated may treat the former conjoined twin as an ... looking at how plants determine who is a competitor when competing ... researcher in plant ecology. "There is no reason for roots to ...
Cached Biology News:Experimental shingles vaccine proves effective in nationwide study 2Experimental shingles vaccine proves effective in nationwide study 3Experimental shingles vaccine proves effective in nationwide study 4Less virulent strains of avian influenza can infect humans 2Plants discriminate between self and non self 2
Request Info...
... Chemicon's 3243 provides all the materials necessary ... use in CMV antigen studies analysis. Kit ... - (Catalog No. 5122) One bottle containing 220 ... Fixation Solution (5X) - (Catalog No. 5113) ...
... For use with suspension (non-adherent) ... uses vacuum filtration or centrifugation ... media. Compatible with 96-well ... in larger package sizes and ...
... The Zero Background/Kan Cloning ... with kanamycin resistance for selection ... vector utilizes positive selection to ... contains all of the reagents ...
Biology Products: